← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #407 OF 1,000 MOST-CITED

Components withheld from use pending release

FDA cited this observation 62 times across 58 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs62
BY FISCAL YEAR
FY20263
FY20257
FY20245
FY20233
FY20226
FY20213
FY20204
FY20194
FY20189
FY20178
FY201610

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 6.5× the rate of the average FDA-cited firm (50.0% vs 7.7%), across 58 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Each lot of components, drug product containers and closures is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit.

KDC/ONE SOCAL LABORATORIES, LLC · Walnut, California · Drugs · 2026-04-14

Each lot of components is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit.

Smith & Nephew Wound Management · Fort Worth, Texas · Drugs · 2026-02-26

Each lot of components is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit.

Merle Norman Cosmetics, Inc. · Los Angeles, California · Drugs · 2025-11-21

Each lot of components is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit.

Specialty Formulations & Manufacturing, LLC · Phoenix, Arizona · Drugs · 2025-09-12

Each lot of components is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit.

AQ USA, Inc. · Lynden, Washington · Drugs · 2025-08-12

Each lot of components is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit.

Voyant Beauty, Inc. · Etobicoke · Drugs · 2025-05-30

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →